US Patent

US10195205 — Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases

Method of Use · Assigned to Nerre Therapeutics Ltd · Expires 2036-05-18 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of dual NK-1/NK-3 receptor antagonists for treating sex-hormone dependent diseases.

USPTO Abstract

This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.

Drugs covered by this patent

elinzanetant (ELINZANETANT)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3622`	—	elinzanetant

Patent Metadata

Patent number: US10195205
Jurisdiction: US
Classification: Method of Use
Expires: 2036-05-18
Drug substance claim: No
Drug product claim: No
Assignee: Nerre Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.